6 November 2025 - Sanofi is pleased to announce that Quebec has added Rezurock (belumosudil tablets) to the list of medications covered by the Régie de l'assurance maladie du Québec (RAMQ) for adult and paediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

The specific criteria for reimbursement is available on the RAMQ website.

Read Sanofi press release